Parabilis Medicines Inc., a clinical-stage developer of cancer therapies, raises nearly $745 million in a US initial public offering that is upsized and priced above its marketed range, along with a private placement. Multiple reports describe the transaction as both an IPO and an accompanying placement, with the final pricing set higher than what investors had been told during marketing. After the deal, the company’s shares begin trading and rise sharply in their debut, with one report citing a jump of as much as 67% during early trading. The reports characterize the pricing and size of the offering as above expectations, indicating strong investor demand at the time of pricing. Parabilis is not reported as having an approved product; instead, it is described as a clinical-stage cancer drug developer. Overall, the coverage centers on the amount raised, the upsized nature of the offering, the above-range pricing, and the initial market reaction to the company’s stock on listing.